GSK2033

Protein target name:

LXR-alpha, LXR-beta

Mechanism of action:

AntagonistInverse Agonistmix Agonist/Antagonist in vivo

Recommended Concentration for use in cells:

>100 nM

Probe Availability

MedchemExpress

TOCRIS

Probe Information

Target and Probe Information

Target Details

Target class:

Hormone pathway

Subclass:

Hormone receptor

HUGO ID:

HGNC:7965 HGNC:7966

Entrez gene ID:

7376 10062

UNIPROT ID:

P55055 Q13133

Target alias:

LXR-b, LXRB, NER, NER-I, RIP15, UNR, LXR-a, LXRA, RLD-1

Probe Details

Chemical Probes Portal ID:

CPP1776

Probe alias:

Compound 17

PubChem CID:

46203250

ChEMBL ID:

CHEMBL1093266

SMILES string:

CC1=CC(=C(C(=C1)C)S(=O)(=O)N(CC2=CC=C(C=C2)C3=CC(=CC=C3)S(=O)(=O)C)CC4=CC=C(O4)C(F)(F)F)C

InChi Key:

PSOXOVKYGWBTPB-UHFFFAOYSA-N

Orthogonal probe:

TO901317

PAINs evaluation:

PAINS Free

Physico-chemical properties

NMR:

1H NMR (400 MHz, DMSO-d6) δ ppm 2.27 (s, 3 H), 2.55 (s, 6 H), 3.29 (s, 3 H), 4.34 (s, 2 H), 4.41 (s, 2 H), 6.39 (d, J=3.48 Hz, 1 H), 7.03 (d, J=2.09 Hz, 1 H), 7.07 (s, 2 H), 7.29 (d, J=8.00 Hz, 2 H), 7.61 - 7.82 (m, 3 H), 7.91 (d, J=8.00 Hz, 1 H), 8.01 (d, J=8.00 Hz, 1 H), 8.13 (s, 1 H);

13C NMR (CDCl3) δ 20.1, 22.8, 41.2, 44.6, 50.0, 110.2, 112.4 (JCF = 2.8 Hz), 117.5, 120.2, 125.8, 126.1, 127.5, 129.5, 129.9, 132.1, 132.2, 132.6, 135.6, 138.7, 140.4, 141.3, 142.1, 143.1, 152.8;

19F NMR (CDCl3) δ -64.7

Validation in Cells and Model Organisms

In vitro validation

On target activity

Potency:

pIC50

7.5

Potency assay:

LXR LEADseeker binding assay

PDB ID for probe-target interaction (3D structure):

3L0E

Structure-activity relationship:

yes

In cell validation

On target activity in cells

Potency in cells:

IC50

17 and 52 nM LXRa9 and 10 nM LXRb

Potency assay (cells):

Co-transfection using Luciferase reporter assay, basal gene expression suppression for ABCA1 and SREBP-1c genes

Off target activity in cells

Probe Selectivity in Cell:

GSK2033 was inactive (XC50 > 10 μM) in cellular and biochemical NR assays, including PXR, LRH-1, and FXR.

Toxicity

Cytoxicity assay:

Yes

Notes on cytotoxicity:

no evidence of cell toxicity

In vivo validation

Organism:

C57BL6 DIO mice

Dose:

30 mg/Kg40 mg/Kg50 mg/Kg

Route of delivery:

Intraperitoneal

Plasma half life:

8 h

Systemic clearance:

Clint > 1.0 mL/min/mg pro

Organ of Interest

Organ (O):

Liver

Target engagement assay:

Gal4-LBD cotransfection assay: GSK2033 activated several nuclear receptors including RORγ, FXR, VDR, PXR, CAR, ERα, ERβ, GR, ERRβ, and ERRγ while suppressing the activity of ERRα and PR.

Primary Reference

Reference (doi):

10.1021/jm901797p

Reference (PMID):

20345102 27680310

GSK2033

Probe Availability

Probe Information

Target Details

LXR-b, LXRB, NER, NER-I, RIP15, UNR, LXR-a, LXRA, RLD-1

Probe Details

Physico-chemical properties

In vitro validation

In cell validation

Toxicity

In vivo validation

Primary Reference

Supporting Organizations

Interested in supporting the portal?

Search form

GSK2033

Probe Availability

Probe Information

Target Details

LXR-b, LXRB, NER, NER-I, RIP15, UNR, LXR-a, LXRA, RLD-1

Probe Details

Physico-chemical properties

In vitro validation

In cell validation

Toxicity

In vivo validation

Primary Reference

Supporting Organizations

Interested in supporting the portal?